3 Pathology Network, Cardiac-Led Hospitals and Integrated Care Leader Stocks With a Strong Future Roadmap: Dr. Lal PathLabs, Fortis Healthcare and Apollo Hospitals Enterprise
- October 22, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Dr. Lal PathLabs, Fortis Healthcare and Apollo Hospitals Enterprise: ROE of 10.5% to 20.5% and FY22 to FY26 revenue CAGR of 7.6% to 14.6%. Prices as of 21 Oct 2026.
Quick Answer
The three pathology and hospital care stocks to watch are Dr. Lal PathLabs, Fortis Healthcare and Apollo Hospitals Enterprise. Their return on equity ranges from 10.5% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 14.6%. Apollo Hospitals Enterprise leads on both return on equity at 20.5% and revenue growth at 14.6% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.
Pathology and hospital care stocks let investors follow the companies that test patients and the companies that treat them. Dr. Lal PathLabs, Fortis Healthcare and Apollo Hospitals Enterprise cover a national reference laboratory network and two of India’s largest private hospital groups.
This list covers three pathology and hospital care stocks with complete current figures: Dr. Lal PathLabs, Fortis Healthcare and Apollo Hospitals Enterprise. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pathology and Hospital Care Stocks?
Pathology and hospital care stocks are listed companies that run diagnostic laboratories or hospitals on a commercial basis. Their earnings depend on test volumes, bed capacity, occupancy and the mix of procedures.
Pathology and Hospital Care Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Dr. Lal PathLabs | 1,836.1 | 30,949 | 56.6 | 59.6 | 20.1 | 0.08 |
| Fortis Healthcare | 729 | 55,554 | 51.9 | 59.6 | 10.5 | 0.35 |
| Apollo Hospitals Enterprise | 7,600 | 110,757 | 51.0 | 59.6 | 20.5 | 0.90 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing pathology and hospital care stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pathology and hospital care stocks can use the coming numbers to test whether growth is holding.
Why Do Pathology and Hospital Care Stocks Have a Strong Roadmap in India?
Pathology and hospital care stocks have a strong roadmap in India because health awareness, insurance cover and demand for advanced treatment are rising faster than the supply of organised labs and hospital beds.
- Preventive testing. More people take regular health checks, which lifts test volumes.
- Capacity additions. New beds and collection centres widen reach in proven cities.
- Complex care. Cardiac, cancer and neuro treatments raise revenue per patient.
Why Dr. Lal PathLabs Features Among These Pathology and Hospital Care Stocks
Among the pathology and hospital care stocks on this list, Dr. Lal PathLabs is one of India’s best-known diagnostics companies, operating a national reference laboratory with a hub-and-spoke network of labs, patient service centres and collection points.
Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%.
In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6.
Roadmap: Its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.
What to watch: Follow test volumes per patient and the balance between routine and specialised tests.
Why Fortis Healthcare Features Among These Pathology and Hospital Care Stocks
Among the reference laboratory shares on this list, Fortis Healthcare operates a network of multi-specialty hospitals across India, with strengths in cardiac sciences, oncology, neurosciences and orthopaedics, and it also runs a diagnostics business.
In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%.
Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6.
Roadmap: The company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.
What to watch: Track bed additions, occupancy and revenue per occupied bed.
Why Apollo Hospitals Enterprise Features Among These Pathology and Hospital Care Stocks
Among the three companies on this list, Apollo Hospitals Enterprise is India’s largest private healthcare group, running a network of hospitals along with a pharmacy chain, diagnostics, primary care clinics and a digital health platform.
The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6.
Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore.
Roadmap: The company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.
What to watch: Track bed additions and occupancy and the growth of the pharmacy and digital health businesses.
Dr. Lal PathLabs vs Fortis Healthcare vs Apollo Hospitals Enterprise on Key Financials
The table below sets the three pathology and hospital care stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Dr. Lal PathLabs | 2,140 | 2,864 | 7.6% | 510 | 17.8% |
| Fortis Healthcare | 5,745 | 9,178 | 12.4% | 1,064 | 11.6% |
| Apollo Hospitals Enterprise | 14,741 | 25,420 | 14.6% | 2,003 | 7.9% |
Apollo Hospitals Enterprise posts the highest return on equity in this group at 20.5%. Apollo Hospitals Enterprise combines the largest FY26 revenue at Rs 25,420 crore with the fastest revenue growth, a 14.6% compound annual rate. A useful habit with pathology and hospital care stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several tertiary care hospital stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Dr. Lal PathLabs | 698 | 830 | 18.9% |
| Fortis Healthcare | 2,182 | 2,560 | 17.3% |
| Apollo Hospitals Enterprise | 5,882 | 7,092 | 20.6% |
Key Risks to Check Before Investing in Pathology and Hospital Care Stocks
Every theme carries risks that deserve a check before any decision. For these pathology and hospital care stocks, the main points are: Long-term reference laboratory shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Ramp-up timing. New hospitals and labs take time to reach stable utilisation.
- Doctor availability. Specialist doctors are central to growth and hard to attract.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pathology and hospital care stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pathology and Hospital Care Stocks
Pathology and hospital care stocks reward investors who follow test volumes, occupancy and bed additions together. Dr. Lal PathLabs, Fortis Healthcare and Apollo Hospitals Enterprise each have a clear path to wider reach. Based on the 21 October 2026 close, Dr. Lal PathLabs trades at Rs 1,836.1, Fortis Healthcare at Rs 729 and Apollo Hospitals Enterprise at Rs 7,600. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pathology and hospital care stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pathology and hospital care stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pathology and hospital care stocks?
Ans. Pathology and hospital care stocks are listed companies that run diagnostic laboratories or hospitals on a commercial basis. Their earnings depend on test volumes, bed capacity, occupancy and the mix of procedures. This list looks at three of them, Dr. Lal PathLabs, Fortis Healthcare and Apollo Hospitals Enterprise, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.
Which pathology and hospital care stocks are covered in this list?
Ans. This list covers Dr. Lal PathLabs, Fortis Healthcare and Apollo Hospitals Enterprise. Based on the 21 October 2026 close, Dr. Lal PathLabs traded at Rs 1,836.1, Fortis Healthcare at Rs 729 and Apollo Hospitals Enterprise at Rs 7,600. Their return on equity ranges from 10.5% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 14.6%.
Why do pathology and hospital care stocks have a strong future roadmap in India?
Ans. Pathology and hospital care stocks have a strong roadmap in India because health awareness, insurance cover and demand for advanced treatment are rising faster than the supply of organised labs and hospital beds. The main drivers are as follows. Preventive testing. More people take regular health checks, which lifts test volumes. Capacity additions. New beds and collection centres widen reach in proven cities. Complex care. Cardiac, cancer and neuro treatments raise revenue per patient. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Dr. Lal PathLabs performed financially?
Ans. Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.
How has Fortis Healthcare performed financially?
Ans. Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6. Looking ahead, the company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.
How has Apollo Hospitals Enterprise performed financially?
Ans. Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6. Looking ahead, the company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.
What risks should investors check before buying pathology and hospital care stocks?
Ans. Investors should check a few risks before buying pathology and hospital care stocks. Ramp-up timing. New hospitals and labs take time to reach stable utilisation. Doctor availability. Specialist doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pathology and hospital care stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
